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Abstract 
Aortic aneurysms, which lead to aortic dissections and ruptures if left untreated, are among the most life 
threatening forms of cardiovascular disease. Thoracic aortic aneurysm is a prominent clinical feature of several 
hereditary connective tissue disorders, including Marfan syndrome (MFS). MFS is caused by mutations in 
FBN1, which encodes fibrillin-1, an important extracellular matrix protein. Through the study of MFS mouse 
models and diseases related to MFS, it became clear that dysregulated TGF-β signaling contributes significantly 
to the pathogenesis of thoracic aortic aneurysms.  
Thoracic aortic and other aneurysms do also occur in autosomal dominant polycystic kidney disease (ADPKD). 
Mutations in PKD1 or PKD2 are responsible for ADPKD. The function of the polycystins, the proteins encoded 
by these two genes, is not clear yet, but an upregulation of TGF-β signaling has also been suggested as a 
pathogenetic mechanism. Although the main manifestation of ADPKD consists of renal cysts, a clear 
cardiovascular involvement with aneurysm formation has been demonstrated. Vice versa, kidney cysts have been 
observed in MFS. This clinical overlap suggests a mechanistic link between ADPKD and MFS. This link 
provides interesting opportunities for investigations on the pathogenic mechanisms of both diseases, more in 
particular the mechanisms leading to formation of thoracic aortic aneurysms. 
 
Keywords: Marfan Syndrome, autosomal dominant polycystic kidney disease, TGF-β signaling, FBN1, PKD1, 
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INTRODUCTION 
 
 Cardiovascular disease is the most 
prominent cause of death in Western 
society (1). One of the most life 
threatening forms consists of aortic 
aneurysms as these lead to aortic 
dissections and ruptures if left untreated 
(2). Thoracic aortic aneurysm is considered 
as a characteristic clinical feature of 
several hereditary connective tissue 
disorders, including Marfan syndrome 
(MFS; MIM# 154700), Ehlers-Danlos 
syndrome (EDS; MIM# 130000) and 
Loeys-Dietz syndrome (LDS; MIM# 
609192) (1).  
 On the other hand, autosomal 
dominant polycystic kidney disease 
(ADPKD; MIM# 173900, MIM# 613095) 
is one of the most frequent human 
hereditary disorders, with a prevalence of 
circa 1/500-1/1000 (3). The disease mainly 
manifests in the kidneys (cyst formation) 
but is also characterized by various extra 
renal symptoms including cysts in the liver 
and spleen and a cardiovascular 
involvement (4). Indeed, a study on 62 
deceased ADPKD patients has shown 
cardiovascular defects in 27% of the 
autopsies (5). Cardiovascular defects 
comprise mitral valve prolapse (up to 25% 
compared to 10% in healthy controls (p-
value = 0,005) (6)), congestive heart 
failure, myocardium hypertrophy, 
aneurysms of the coronary or cervical 
cephalic arteries, cerebral aneurysms (up to 
10%) and dissections of the thoracic (p-
value = 0,034 (7)) and abdominal aorta. 
Importantly, thoracic aortic dissections are 
seven times more frequent in ADPKD 
patients than in the general population, 
while in 1-10% of all ADPKD patients 
aortic aneurysms are found (8-11). This 
demonstrates a clear cardiovascular 
involvement in ADPKD patients. Vice 
versa, in 50-60% of the MFS patients, 
cysts are observed in the kidneys (12). This 
clinical overlap suggests a pathogenetic 
link between ADPKD and MFS. 
 
CLINICAL AND GENETIC 
FEATURES OF MARFAN 
SYNDROME 
 
 Marfan syndrome (MFS) is a 
multisystemic connective tissue disorder 
affecting the skeletal, ocular and 
cardiovascular system. It exhibits an 
autosomal dominant inheritance pattern (2) 
and has an estimated prevalence of 1 in 
5000 individuals (13, 14). The major 
skeletal features of MFS include skeletal 
overgrowth leading to disproportionate 
body dimensions, scoliosis, pectus 
deformities and long digits 
(arachnodactyly) (15). As a consequence 
of the skeletal alterations, pulmonary 
manifestations may arise. About 60% of 
the MFS patients are affected by lens 
dislocation which can result in retinal 
detachment and glaucoma. The most life 
threatening complication in MFS patients 
is progressive dilatation of the aorta 
leading to aneurysm formation and 
eventually aortic dissection and rupture. 
Apart from aortic dilatation, approximately 
80% of the MFS patients suffer from mitral 
valve prolapse (16). 
 MFS is a pleiotropic disease, 
making an accurate diagnosis sometimes 
P Belg Roy Acad Med Vol. 2:179-197   D. Schepers et al. 
___________________________________________________________________________ 
181 
difficult. To facilitate the diagnosis of MFS 
patients, the Berlin nosology was 
formulated in 1986 (17). Because 
weaknesses of these criteria had emerged, 
they were revised and edited in 1996, 
giving rise to the Ghent nosology (15). The 
latter set of criteria are mainly based on 
major and minor clinical findings in the 
different affected tissues including the 
cardiovascular, skeletal, ocular, and 
pulmonary system in addition to dura and 
skin. Major manifestations comprised 
ectopia lentis, aortic root dilatation or dural 
ectasia. In 2010, the Ghent criteria have 
been revised, leading to straigthforward 
diagnostic rules and putting more emphasis 
on the cardiovascular manifestations and 
molecular analysis (18). Four possible 
combinations can lead to a diagnosis of 
MFS in a proband: aortic root dilatation 
(Z-score >2) and ectopia lentis, aortic root 
dilation with an FBN1 mutation, aortic root 
dilation with sufficient systemic findings 
(score of 7 or more on the systemic scale; 
for details see (18)) or finally ectopia lentis 
with an FBN1 mutation that has been 
associated with aortic root dilation. 
 Since FBN1 was identified as the 
MFS causing gene in 1991, more than 
1000 different mutations in FBN1 have 
been described (19). FBN1 encodes the 
fibrillin-1 protein, an important component 
of the extracellular matrix (ECM). The 
protein contains various repetitive domains 
including cb EGF-like (calcium binding 
epidermal growth factor) domains, non-cb 
EGF-like domains, hybrid motifs and 
LTBP-like (latent transforming growth 
factor beta binding protein) domains 
characterized by an 8-cysteine domain. 
The fourth LTBP-like domain contains an 
RGD motif (arginine-glycine-aspartic acid) 
responsible for binding of fibrillin-1 to 
integrin (Fig. 1A) (20, 21). Fibrillin-1 also 
interacts with many other ECM proteins 
such as elastin, fibulins, LTBPs and 
microfibril associated proteoglycans (22-
24). 
 
CLINICAL AND GENETIC 
FEATURES OF AUTOSOMAL 
DOMINANT POLYCYSTIC KIDNEY 
DISEASE (ADPKD) 
 
 ADPKD has an estimated 
prevalence of 1 in 500 to 1000 individuals, 
making it the most frequent hereditary 
renal disorder (25, 26). It is characterized 
by cyst formation in the kidneys and 
various extrarenal symptoms including 
cerebral, thoracic and abdominal aortic 
aneurysms (3, 27, 28). Cysts are not 
necessarily harmful and actually quite 
common in the general population, 
particularly in older people. Study of the 
natural history revealed that almost 12% of 
the population has at least one renal cyst 
(29). Also within the general population, 
renal cysts are more common in men than 
in women and their number and size 
increase with age (30). In ADPKD 
patients, 27% of autopsies show 
cardiovascular defects, including mitral 
valve prolapse (up to 25%), congestive 
heart failure, myocardium hypertrophy, 
aneurysms of the coronary or cervical 
cephalic arteries, cerebral aneurysms (up to 
10%) and dissections of the thoracic and 
abdominal aorta (5).   
 ADPKD is mainly caused by PKD1 
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(85-90%) or PKD2 (10-15%) mutations 
(28, 31-33). A small fraction (~ 1%) of 
ADPKD families cannot be linked to one 
of the known loci, suggesting the existence 
of a third disease causing gene (34-36).  
 PKD1 encodes the polycystin-1 
(PC1) protein, an integral membrane 
glycoprotein (37-39). PC1 has the structure 
of a receptor or an adhesion molecule (see 
Fig. 1B) and mediates cell-cell and cell 
ECM interactions. It contains 16 
immunoglobulin-like domains (also called 
PKD repeats), a receptor for egg-jelly 
domain and a G-protein linked receptor 
proteolytic site (GPS). It also has a long 
extracellular N-terminal region, 11 
transmembrane domains, and a short 
intracellular C-terminal region (3, 38). This 
cytoplasmic tail comprises a coiled-coil 
domain and a G-protein domain, which 
plays an important role in signal 
transduction. PC1 is expressed in the 
primary cilia, cytoplasmic vesicles, the 
plasma membrane near focal adhesions, 
desmosome adherens junctions and 
possibly the endoplasmatic reticulum (ER) 
and nuclei (3). It has been suggested that 
PC1 may regulate the mechanical adhesion 
strength between cells to control the 
formation of stable actin associated 
adherens junctions (40). 
 
 
Figure 1. Fig. 1: (A) Structure of fibrillin-1, showing the different domain structures. (B) Structure of PC1 (left) 
and PC2 (right) and their interactions via coiled-coil domains in the C-terminus. Figures are not drawn to scale. 
P Belg Roy Acad Med Vol. 2:179-197   D. Schepers et al. 
___________________________________________________________________________ 
183 
 PKD2 encodes the polycystin-2 
(PC2) protein, an integral membrane 
glycoprotein as well (3, 41, 42). PC2 
consists of a short N-terminal cytoplasmic 
region with a ciliary targeting motif, six 
transmembrane domains and a short C-
terminal tail (43). The latter has a calcium 
(Ca
2+
) binding motif (EF-hand), an ER 
retention motif and a coiled-coil domain, 
responsible for various protein interactions 
(44, 45). PC2 is a non-selective cation 
channel transporting Ca
2+
 and is mainly 
localized in the ER, but it is also found in 
the primary cilia and plasma membrane of 
the renal tubuli (46, 47).  
 Both PC1 and PC2 are members of 
the TRPP family (Transient Receptor 
Potential Polycystic), a subfamily of the 
transient receptor potential (TRP) 
channels. Both proteins interact with each 
other via their C-termini, resulting in a 
complex structure formed in the primary 
cilium (48, 49). The interaction between 
PC1 and PC2 depends on the integrity of 
the coiled-coil domain in the C-terminus of 
PC1. Therefore, a first hypothesis suggests 
that PC1 may be functioning as a receptor 
controlling the cation channel activity of 
PC2 (42). A second hypothesis states that 
the polycystin complex may function as a 
mechanoreceptor sensing the fluid-flow in 
the lumen of the tubuli. This may trigger 
Ca
2+
 influx through the PC2 channel, 
hereby regulating the intracellular Ca
2+
 and 
cyclic AMP amounts (50). In this way, the 
PC1/PC2 complex can respond to flow-
induced mechanosensory stimuli. 
Moreover, it has been shown that cultured 
kidney epithelial cells with mutations in 
Pkd1, do not activate flow-dependent Ca
2+
 
signaling (50). A third possibility is that 
PC1 and PC2 rather have a ciliary 
function. Both PC1 and PC2 are localized 
to the primary cilia of renal epithelia and it 
is known that cilia act as sensory 
organelles. Support for this hypothesis 
resulted from a study in which Kif3a 
deficiency, a protein of the kinesin-2 motor 
complex required for cilia homeostasis, 
resulted in cyst formation (51). 
 
CLINICAL OVERLAP BETWEEN 
MFS AND ADPKD 
 
 As mentioned before, 
cardiovascular abnormalities are fairly 
common in ADPKD patients. A familial 
clustering of cerebral aneurysms was 
observed in ADPKD patients (52). Several 
case studies have shown an association 
between aortic aneurysm/dissection and 
ADPKD (Table 1). In 1 to 10% of ADPKD 
patients, aortic aneurysms are found (9-
11). Moreover, dissection of the thoracic 
aorta is seven times more frequent in 
ADPKD patients (8). From the overview in 
Table 1, it is clear that there is no obvious 
association between the occurrence of 
aortic dissection and the gender, age, the 
degree of kidney dysfunction, the presence 
of hypertension or linkage to PKD1 or 
PKD2. Both type A and B dissections have 
been described in the presence or absence 
of cystic media degeneration. These data 
suggest that genetic modifiers confer the 
association of aortic aneurysms/dissection 
in ADPKD. On the other hand, MFS 
patients have more renal cysts and at an 
earlier age compared to healthy controls as 
demonstrated in a study performed on 69
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Case report Gender 
Age at 
dissection 
Hypertension ESRD PKD1 or 2 
Aortic 
histology 
Type of 
dissection 
(Stanford) 
Biagini (95) Female 63 No  No    
 Female 45 
Mild arterial 
hypertension 
No    
Somlo (53) Female 60  No    
 Male 38  Yes    
 Male 31  No  
Cystic medial 
necrosis 
A 
Hartman 
(96) 
Male 72  Yes    
Paynter (97) Female 36 Yes (200/120) Yes  Normal B 
Osawa (98)    Yes    
Adeola (99) Male 42 Yes    B 
Lee (100) Male 58 Yes   
Cystic medial 
myxoid 
degeneration 
A 
Peczkowska 
(101) 
Male 54 Yes 
Creatinin 
226 
PKD1 
No cystic 
medial 
necrosis 
A 
 Male 47 Yes 
Normal 
creatinin 
PKD1  A 
Keuleers 
(102) 
Female 54 No No 
No genetic 
confirmation 
Segmental 
arterial 
mediolysis  
A 
Minami 
(103) 
Male 55  Yes   A 
Ramineni 
(104) 
Female 44 Yes    B 
Gignon 
(105) 
Male 43     A 
Fukunaga 
(106) 
Male 44 Yes   
Dissection of 
media 
B 
Table 1. Case reports of thoracic aortic aneurysms and dissections in combination with ADPKD 
 
MFS patients; in 59,4% of the MFS 
patients, renal cysts were present compared 
to 30,4% of the controls (12). Although 
renal cysts are seldom clinically significant 
in MFS, these findings suggest a molecular 
link between the vascular findings in MFS 
and cyst formation. This was further 
supported by the description of pedigrees 
in which ADPKD and connective tissue 
disorders (skeletal overgrowth and aortic 
aneurysms) appear to cosegregate. In one 
of these families linkage with PKD1 was 
found, while linkage with FBN1 was 
excluded (53). In another family, 
independent segregation of the kidney 
phenotype with PKD1 and of the aneurysm 
phenotype with FBN1 occurred (54).  
 Interestingly, also in the Loeys-
Dietz syndrome (LDS) there are 
indications of a clinical overlap with 
ADPKD. LDS is another thoracic aortic 
aneurysm syndrome, characterized by 
hypertelorism, a cleft palate and the 
development of aneurysms. It is caused by 
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mutations in the TGFBR1 or 2 gene, 
encoding the TGF-β1 or 2 receptors (55). 
Unlike MFS patients, LDS patients do not 
present with lens dislocations and the 
skeletal overgrowth is less explicit. As 
cysts were also found in the kidneys of 
LDS patients (H. Dietz, personal 
communication), this provides another 
indication of an important role for the 
ECM in the development of renal cysts.  
 
LESSONS LEARNED FROM MFS 
AND PKD MOUSE MODELS 
 
 New insights and confirmation of 
hypotheses concerning the molecular and 
cellular mechanisms underlying the MFS 
and ADPKD pathology have been gained 
through the generation and study of mutant 
mouse lines (Table 2). 
 
MOUSE MODELS OF MFS 
 
 One of the first MFS models was 
the so called mgΔ mouse (56). Because 
heterozygous mgΔ animals did not express 
a MFS-like phenotype and homozygous 
mice deceased early in life, the mgR 
mouse was generated. This hypomorphic 
mouse, expressing only 15% of normal 
Fbn1 levels, survived significantly longer 
than the mgΔ mice and showed a MFS-like 
aortic phenotype with medial calcification, 
intimal hyperplasia and inflammatory
 
Mouse Genetic engineering Heterozygous  
mice 
Homozygous 
mice 
Conclusion Reference 
Marfan      
mg Deletion of Fbn1 
exons 19 to 24  
Normal phenotype Perinatal death 
because of 
vascular 
complications 
Difficult to 
study because 
of prenatal 
lethality 
57 
mgR Hypomorphic Fbn1 
allele (expresses 15% 
of normal levels) 
Normal phenotype Survive longer as 
mg mice 
Medial 
calcification  
Intimal 
hyperplasia 
Inflammatory 
responses 
Threshold 
hypothesis 
Fbn1 
functions in 
homeostasis of 
elastic tissues 
 
58 
Fbn1
C1039G/+
 Fbn1 c.1039C>G From 2 months of 
age: 
Elastic fiber 
fragmentation 
Thickening of 
aortic wall 
No intimal 
hyperplasia 
No Inflammation 
No aortic dissection 
Not applicable Loss of 
function 
contributes to 
disease 
mechanism 
Currently 
preferred MFS 
animal model 
61 
Tsk Naturally occurring 
duplication in Fbn1 
resulting in a larger 
protein 
Thickened skin 
Bone overgrowth 
Lung emphysema 
No vascular 
abnormalities 
Not applicable Threshold 
hypothesis 
Naturally 
occurring SSS 
animal model 
60 
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ADPKD      
Pkd1
del34
 Deletion of Pkd1 
exon 34 
Normal phenotype 
Few kidney cysts at 
older age 
Perinatal death 
because of: 
Enlarged kidneys 
Pancreatic cysts 
Pulmonary 
hypoplasia 
No vascular 
abnormalities 
Difficult to 
study because 
of lethality 
66, 67 
Pkd1
L
 Premature stop codon 
in Pkd1 exon 43 
Normal phenotype Embryonic lethal 
with: 
Edema 
Focal vascular 
leaks 
Hemorrhage 
PC1 functions 
in tissue 
integrity 
 
68 
Pkd1
del17-
21βgeo
 
Deletion of Pkd1 
exons 17 to 21 
Renal cysts 
Occasionally liver 
cysts 
Embryonic lethal 
with: 
Disorganized 
myocardium 
Abnormal atrio-
ventricular 
septation 
First ADPKD 
animal model 
69 
Pkd1
-
 Deletion of Pkd1 
exons 2 to 6 
Subtle endothelial 
dysfunction 
Defective NOx 
production 
Embryonic lethal 
with: 
Hemorrhage 
Progressive renal 
cystogenesis 
Difficult to 
study 
70 
Pkd1
nl
 Hypomorphic Pkd1 
allele (expresses 20% 
of normal levels) 
Not applicable Viable 
Renal, liver, 
pancreatic cysts 
Cardiovascular 
abnormalities 
Good ADPKD 
animal model 
71 
Pkd2
WS25
 Disrupted exon 1 in 
tandem with WT 
exon 1 
Renal cysts Renal cysts 
(more severe) 
Loss of 
capacity to 
express PC2 
leads to cyst 
formation 
72 
Pkd2
-
 Deletion of Pkd2 
exon 1 
Renal cysts 
Early death 
Embryonic lethal 
with: 
Structural cardiac 
defects 
Renal and 
pancreatic cysts 
Haplo-
insufficiency 
is mechanism  
73 
Table 2: Existing mouse models for MFS and ADPKD 
 
responses (fibroproliferation and 
elastolysis) (57). Because heterozygous 
mgR mutant animals expressed a normal 
phenotype throughout life, a threshold 
hypothesis was suggested in which the 
relative amount of functionally normal 
fibrillin-1 is decisive for MFS severity. 
Detailed study of the elastic vessels from 
both mgR mice and MFS patients revealed 
loss of cell attachments at the surface of 
elastic laminae, causing morphological 
changes in neighboring cells (58). This 
suggested an important role for fibrillin-1 
in the homeostasis of elastic tissues. 
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Further support for the threshold 
hypothesis came from the Tight skin (Tsk) 
mouse, characterized by thickened skin, 
bone overgrowth and lung emphysema 
(59). Heterozygous Tsk mice express a 
decreased amount of functional 
microfibrils, hereby exceeding the 
threshold levels for bone overgrowth and 
lung emphysema, but not for vascular 
abnormalities. Because mgΔ and mgR 
mice both rely on homozygosity of the 
mutant allele for expression of a 
phenotype, a heterozygous MFS mouse 
model was generated: the Fbn1
C1039G/+
 
mouse (60). These mice had a normal life 
span, while elastic fiber fragmentation and 
thickening of the aortic wall was 
significant starting at 2 months of age. 
Intimal hyperplasia and aortic wall 
inflammation were not observed. 
Unfortunately, also aortic dissections did 
not occur. As transgenic addition of the 
wild type fibrillin-1 allele to the 
Fbn1
C1039G/+
 mice resulted in rescue of the 
MFS phenotype, loss-of-function was 
confirmed as the disease mechanism in 
MFS pathogenesis.  
 
INVOLVEMENT OF DYSREGULATED 
TGF-Β SIGNALING IN MFS 
PATHOGENESIS 
 
 For a long time it was assumed that 
MFS was caused by pure structural 
deficiency of the microfibrils. This 
provided a plausible explanation for some 
manifestations of MFS, such as lens 
dislocation and aortic aneurysm, but 
others, including skeletal overgrowth, 
could not be explained by loss of structural 
tissue integrity. Studies on the Fbn1
C1039G/+
 
mouse model demonstrated that increased 
TGF-β signaling played an important role 
in the aorta pathology (61, 62) and that 
fibrillin-1 is thus not only a structural 
component of the ECM but also a key 
regulator of TGF-β activation (21, 63) (see 
Fig. 2). The key experiment involved 
rescue of the mutant phenotype in Fbn1 
deficient mice by the administration of 
TGF-β-neutralizing antibodies (62). This 
mutant phenotype included impaired distal 
airspace septation in the respiratory tract 
(62), and elastic fiber fragmentation, 
aneurysms (64) and mitral valve prolapse 
(61) in the cardiovascular system. 
 
MOUSE MODELS OF ADPKD 
 
 Pkd1
del34 
was the first Pkd1 mouse 
(65). Heterozygous Pkd1
del34/+
 mice have a 
normal phenotype although a few kidney 
cysts developed at older age (66), while 
homozygous animals died early in the 
perinatal period. No vascular abnormalities 
were observed. In a second Pkd1 mouse 
model, homozygous mice (Pkd1
L/L
) died in 
utero between E14.5 and E15.5 (67). The 
animals exhibited edema, focal vascular 
leaks and hemorrhage, indicating that PC1 
has an important role in maintenance of 
vascular tissue integrity. Homozygosity for 
a third mutant Pkd1 allele (Pkd1
del17-21βgeo
) 
also turned out to be embryonic lethal, but 
both homozygous and heterozygous 
mutant mice developed renal cysts (68). 
Homozygous mutant mice of the fourth 
Pkd1 mouse model (Pkd1
-/-
) died from 
E14.5 onwards (69). Surviving Pkd1
-/-
mice 
developed renal cysts starting from E15.5, 
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Figure 2: Overview of the TGF-β pathways involved in the pathogenesis of MFS. TGF-β is the prototype of a 
family of secreted polypeptide growth factors essential in development, cell growth, differentiation, migration, 
apoptosis and ECM production (74, 75). TGF-β is secreted as part of a latent complex, consisting of TGF-β, 
LAP-β (latency associated protein) and LTBP (latent TGF-β binding protein), and binds to the ECM. Once 
activated, TGF-β binds to the cell surface receptors, TβRI and TβRII (76). Smads (combination of the C. elegans 
Sma protein and the Drosophila Mad (Mothers against decapenthaplegic) protein) are transcription factors 
shuttling between the cytoplasm and nucleus which regulate the intracellular responses with regard to TGF-β 
(77-80). TGF-β can activate two pathways: the canonical (indicated in blue) and the non-canonical (indicated in 
green). In the canonical signaling pathway, Smad2 and/or Smad3 are phosphorylated by TβRI/II, followed by 
binding of Smad4. The Smad2/3-Smad4 complex translocates to the nucleus where transcription of Smad 
dependent genes occurs (81). The non-canonical (alternative) TGF-β pathways include the RhoA and MAPK 
cascades (ERK, JNK and p38) (82-84). 
 
which increased in number and size up to 
E18.5. Next, a hypomorphic Pkd1 mutant 
model (Pkd1
nl
), expressing only 20% of 
normal PC1, was generated (70). In 
contrast to the previous Pkd1 mutant 
mouse models, Pkd1
nl
 mice were viable 
and presented renal, liver and pancreatic 
cysts. They also showed cardiovascular 
abnormalities, in line with the human 
ADPKD phenotype. These findings 
demonstrate that a decreased Pkd1 
expression level is sufficient to cause 
polycystic kidneys and vascular 
abnormalities.  
 In the first Pkd2 mouse model 
(Pkd2
WS25
), about half of the homozygous 
and heterozygous mutant animals 
developed renal cysts, with cyst formation 
being more severe in the homozygous 
mice. In a minority, liver cysts were 
observed as well (71). PC2 
immunohistochemistry on kidneys of 
Pkd2
+/WS25 
mice with a non-cystic 
phenotype was comparable to that of WT 
mice. In contrast, in kidneys of Pkd2
+/WS25 
mice with a cystic phenotype, a complete 
absence of PC2 immunoreactivity was 
observed in the renal cysts and in cells 
lining the cysts, while the surrounding 
noncystic regions did show PC2 
P Belg Roy Acad Med Vol. 2:179-197   D. Schepers et al. 
___________________________________________________________________________ 
189 
expression. This suggested that tubular 
epithelial cells which lose the complete 
capacity to express PC2 may give rise to 
cysts. The second Pkd2 mouse model 
carried a true null mutation (Pkd2
-
) (72). 
Homozygous mice died at E13.5. Kidney 
cysts development in heterozygous mice 
(Pkd2
+/-
) resulted in renal failure and early 
death. Heterozygous mice without kidney 
cysts had an intermediate survival. These 
findings suggested that haploinsufficiency 
was the disease causing mechanism. 
Further evidence for haploinsufficiency as 
the disease causing mechanism came from 
the evaluation of two rat models 
expressing truncated PC2 (73). 
 
OPPORTUNITIES FOR THE STUDY 
OF ANEURYSM PATHOGENESIS 
FROM THE INTERSECTION OF MFS 
AND ADPKD 
 
ROLE OF TGF-Β IN MFS AND ADPKD 
 
 As described above, dysregulated 
TGF-β signaling is an important 
contributor to MFS pathogenesis. 
Likewise, experiments on ADPKD 
epithelial cells show an increased TGF-β 
activation (85), while also in Pkd1
nl
 mice 
an important role for TGF-β signaling was 
demonstrated in the more advanced stages 
of disease, including cyst progression and 
fibrogenesis (86). This suggests a clear 
contribution of dysregulated TGF-β 
signaling to ADPKD progression. For the 
time being, it is not clear exactly how the 
polycystins fit within this pathogenic 
mechanism, although it is conceivable that 
the polycystins play a role in the ECM. 
The latter hypothesis is built on several 
arguments. First, polycystin 1 has several 
extracellular motifs that may function in 
possible cell-cell and cell-matrix 
interactions (87). Second, an altered 
expression of matrix proteins, such as 
collagen and fibronectin, occurs in 
polycystic kidneys (88, 89). Finally, in 
Pkd1 and Pkd2 deficient zebrafish, a 
persisting expression of multiple collagen 
mRNAs transcripts and low levels of 
collagen-crosslinking inhibitors were 
found, implicating an involvement of the 
polycystins in the modulation of collagen 
expression (90).  
 
ROLE OF PC1/PC2 IN VASCULAR 
REMODELING 
 
 Polycystin 1 and 2 are expressed in 
the smooth muscle cells of the arterial wall 
and in the dense plaques, where they 
anchor the intracellular contractile 
filaments to the extracellular elastic 
lamellae (91, 92). Based on the 
hypomorphic Pkd1
nl
 mouse model, 
Hassane et al. examined vascular 
remodeling in ADPKD (93). These studies 
led to the formulation of a model for 
aneurysm formation in which matrix 
components accumulate between the 
elastic lamellae, followed by an increase of 
smooth muscle cells leading to weakening 
of the vessel wall. Subsequently, 
endothelial cells detached from the elastic 
lamellae in the intima. This leads, in 
combination with the weakened aortic 
media, to a rupture in the intima, giving 
rise to intramural bleeding. Therefore, 
polycystins may play a role in the smooth 
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muscle cell-adhesion complex and the 
maintenance of the structural integrity of 
the vasculature, and thus seem to function 
in vascular homeostasis rather than in 
vascular development (93). 
 Pkd2
+/-
 mice were used to examine 
intracellular Ca
2+
 homeostasis (94). 
Hypertension was surgically induced in 
WT and Pkd2
+/-
 mice. Since the majority 
of Pkd2
+/-
 mice developed cerebral arterial 
lesions compared to only one WT animal, 
loss of PC2 was associated with an 
increased risk of vascular complications. 
Furthermore, Pkd2
+/-
 mice had decreased 
sarcoplasmic reticulum Ca
2+
 storage 
caused by reduced store-operate calcium 
activity. These data support the hypothesis 
that the PC1/PC2 complex might play a 
role in flow-dependent Ca
2+
 regulation. 
Most probably, abnormal intracellular Ca
2+
 
regulation is contributing to the vascular 
phenotype observed in ADPKD. This may 
warrant experiments to deduce the 
intracellular Ca
2+
 levels in MFS mouse 
models as well. 
 In conclusion, although the 
pathogenic mechanisms leading to 
aneurysm formation in MFS and ADPKD 
remain largely undeciphered, it is clear that 
an interesting overlap exists (Fig.3) and 
that this overlap may provide interesting 
opportunities for investigations on the 
pathogenic mechanisms of both diseases. 
 
FUTURE PERSPECTIVES 
 
 Although mutations in PKD1 and 
PKD2 explain the large majority of the 
ADPKD families, further genetic 
heterogeneity has been suggested based on 
the fact that some ADPKD families are not 
linked to either PKD1 or PKD2. But, so far 
the suggested third locus has not been 
identified. The availability of ADPKD 
families with known vascular involvement 
and in whom linkage to the PKD1, PKD2,
 
 
Figure 3. Overlap between the different proteins involved in MFS and ADPKD and their function. 
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FBN1 and TGFBR1/2 loci has been 
excluded, can offer a solution. If these 
families are large enough linkage analysis 
can be performed, possibly resulting in the 
identification of new loci. Additionally, if 
tissue samples from these families are 
available immunohistochemistry can be 
performed, enabling the investigation of 
the contribution of TGF-β in ADPKD 
pathogenesis. If human tissues cannot be 
obtained, experiments on aortic wall tissue 
from different Pkd mouse models can be 
informative. The results of these 
experiments will lead to a better 
understanding of the different pathways 
that are involved in the pathogenesis of 
aneurysm formation in MFS and ADPKD 
and will provide an explanation for the 
intersection of both diseases. 
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